Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The NIMH-MATRICS consensus statement on negative symptoms.

Literature DB >> 16481659

The NIMH-MATRICS consensus statement on negative symptoms.

Brian Kirkpatrick¹, Wayne S Fenton, William T Carpenter, Stephen R Marder.

Abstract

Mesh：

Substances：
Antipsychotic Agents

Year: 2006 PMID： 16481659 PMCID： PMC2632223 DOI： 10.1093/schbul/sbj053

Source DB: PubMed Journal: Schizophr Bull ISSN： 0586-7614 Impact factor: 9.306

× No keyword cloud information.

25 in total

1. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale.

Authors: R M Norman; A K Malla; T McLean; L P Voruganti; L Cortese; E McIntosh; S Cheng; A Rickwood
Journal: Acta Psychiatr Scand Date: 2000-10 Impact factor: 6.392

2. The sensitivity of quality-of-life scale WHOQOL-100 to psychopathological measures in schizophrenia.

Authors: Sibel Orsel; Asena Akdemir; Ihsan Dağ
Journal: Compr Psychiatry Date: 2004 Jan-Feb Impact factor: 3.735

3. Treatment of schizophrenia negative symptoms: future prospects.

Authors: Stephen M Erhart; Stephen R Marder; William T Carpenter
Journal: Schizophr Bull Date: 2006-02-21 Impact factor: 9.306

4. Deficit and nondeficit forms of schizophrenia: the concept.

Authors: W T Carpenter; D W Heinrichs; A M Wagman
Journal: Am J Psychiatry Date: 1988-05 Impact factor: 18.112

Review 5. Schizophrenia and quality of life.

Authors: H Katschnig
Journal: Acta Psychiatr Scand Suppl Date: 2000

Review 6. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia.

Authors: R W Buchanan; W T Carpenter
Journal: J Nerv Ment Dis Date: 1994-04 Impact factor: 2.254

Review 7. Assessing the efficacy of treatments for the deficit syndrome of schizophrenia.

Authors: B Kirkpatrick; A Kopelowicz; R W Buchanan; W T Carpenter
Journal: Neuropsychopharmacology Date: 2000-03 Impact factor: 7.853

Review 8. A separate disease within the syndrome of schizophrenia.

Authors: B Kirkpatrick; R W Buchanan; D E Ross; W T Carpenter
Journal: Arch Gen Psychiatry Date: 2001-02

9. The diagnosis and understanding of schizophrenia. Part III. Speculations on the processes that underlie schizophrenic symptoms and signs.

Authors: J S Strauss; W T Carpenter; J J Bartko
Journal: Schizophr Bull Date: 1974 Impact factor: 9.306

10. Social function in schizophrenia and schizoaffective disorder: associations with personality, symptoms and neurocognition.

Authors: Paul H Lysaker; Louanne W Davis
Journal: Health Qual Life Outcomes Date: 2004-03-16 Impact factor: 3.186

346 in total

1. Negative symptoms and the formation of social affiliative bonds in schizophrenia.

Authors: Julie M McCarthy; Kristen R Bradshaw; Lauren T Catalano; Cristina P Garcia; Asia Malik; Melanie E Bennett; Jack J Blanchard
Journal: Schizophr Res Date: 2017-08-02 Impact factor: 4.939

Review 2. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?

Authors: Joshua T Kantrowitz; Daniel C Javitt
Journal: Brain Res Bull Date: 2010-04-24 Impact factor: 4.077

3. The prospective relationships among intrinsic motivation, neurocognition, and psychosocial functioning in schizophrenia.

Authors: Eri Nakagami; Maanse Hoe; John S Brekke
Journal: Schizophr Bull Date: 2010-05-12 Impact factor: 9.306

Review 10. A meta-analytic review of self-reported, clinician-rated, and performance-based motivation measures in schizophrenia: Are we measuring the same "stuff"?

Authors: Lauren Luther; Ruth L Firmin; Paul H Lysaker; Kyle S Minor; Michelle P Salyers
Journal: Clin Psychol Rev Date: 2018-04-07